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OBJECTIVES The goal of this study was to determine if B-type natriuretic peptide (BNP) levels predict
outcomes of patients admitted with decompensated heart failure.
BACKGROUND Treatment of decompensated congestive heart failure (CHF) has often been based on
titration of drugs to relieve patient’s symptoms, a case that could be made for attempting to
also treat neurohormonal abnormalities. Because BNP reflects both elevated left ventricular
pressure as well as neurohormonal modulation, we hypothesized that BNP might be useful in
assessing outcomes in patients admitted with decompensated CHF.
METHODS We followed 72 patients admitted with decompensated New York Heart Association class III
to IV CHF, measuring daily BNP levels. We then determined the association between initial
BNP measurement and the predischarge or premoribund BNP measurement and subsequent
adverse outcomes (death and 30-day readmission).
RESULTS Of the 72 patients admitted with decompensated CHF, 22 end points occurred (death: n 5
13, readmission: n 5 9). In these patients, BNP levels increased during hospitalization (mean
increase, 233 pg/ml, p , 0.001). In patients without end points, BNP decreased (mean
decrease 215 pg/ml). Univariate analysis revealed that the last measured BNP was strongly
associated with the combined end point. In patients surviving hospitalization, BNP discharge
concentrations were strong predictors of subsequent readmission (area under the receiver
operator curve of 0.73).
CONCLUSIONS In patients admitted with decompensated CHF, changes in BNP levels during treatment are
strong predictors for mortality and early readmission. The results suggest that BNP levels
might be used successfully to guide treatment of patients admitted for decompensated CHF.
(J Am Coll Cardiol 2001;37:386–91) © 2001 by the American College of Cardiology
Heart failure is the leading cause of hospital admission
among patients over the age of 65 years and accounts for 3%
of the total national health care budget, 70% of which comes
from hospitalization (1). Despite advances in treatment,
patients admitted with decompensated heart failure have
significant hospital mortality and early readmission rates
(1–4). This stems, in part, from the fact that there are no
reliable indicators of the adequacy of treatment (5,6).
B-type natriuretic peptide (BNP) is a cardiac neurohor-
mone secreted from membrane granules in the cardiac
ventricles as a response to ventricular volume expansion and
pressure overload (7–9). B-type natriuretic peptide levels
have been shown to be elevated in patients with symptom-
atic left ventricular (LV) dysfunction and correlate to LV
filling pressure, New York Heart Association (NYHA)
classification and prognosis (10–12). Falling BNP levels
reflect beneficial treatment but, until recently, had the same
pitfalls of measurement as other neurohormones and cyto-
kines (13–15).
Using a recently developed rapid BNP assay (Biosite
Diagnostics, San Diego, California), we asked whether
BNP levels might be useful in assessing therapeutic re-
sponses in patients admitted with decompensated conges-
tive heart failure (CHF). To test this hypothesis, we
observed the relationship between BNP measurements per-
formed during hospitalization and serious adverse out-
comes.
METHODS
Patients. Between March 1999 and December 1999, we
identified a convenience sample of 72 male Veterans pa-
tients between 28 and 102 years old (mean age 5 68 6 1.6
years) who had been admitted for CHF (Table 1). Criteria
for inclusion included new-onset CHF confirmed by at least
one cardiologist using standard Framingham criteria or
exacerbation of previously documented CHF. All patients
had to be at least NYHA class III to be included. The initial
BNP level had to be drawn within 24 h of admission and
within 24 h of discharge or death to be included in the
study. Informed consent was obtained from a protocol
approved by the UCSD Institutional Review Board. Inabil-
ity and unwillingness to consent to study participation were
the only two criteria for exclusion. During this period,
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approximately one hundred and ten patients were screened.
Failure to enroll patients was due to the inability to consent
(refusal or intubation) or that the initial BNP was drawn
after the 24 h limit.
Study protocol. Patients were treated in standard fashion
with either oral or intravenous diuretics and vasodilators.
Blood was also sampled whenever treatment changes were
made or the patient’s condition changed (typically, on a
daily basis throughout hospitalization). In patients who died
during hospitalization, the last measured BNP concentra-
tion was considered the “discharge” BNP measurement.
Physicians treating the patients were blinded to the results
of BNP measurements.
Because of the small sample size and the low anticipated
rate of adverse events, this study used a (prespecified)
combined outcome of either death in hospital or death
within 30 days after discharge or readmission to the hospital
facility for CHF within 30 days. At 30 days, patient records
were checked for readmission or death. Events outside
facilities were also tracked by medical records, as patients are
always transferred to the VA when stable. One hundred
percent of patients received complete follow-up at 30 days.
Measurement of BNP plasma levels. For each BNP
measurement, 5 ml of whole blood was collected into tubes
containing potassium EDTA (1 mg/ml blood). B-type
natriuretic peptide was measured using the Triage B-Type
Natriuretic Peptide test (Biosite Diagnostics Inc., San
Diego, California). The Triage BNP test is a fluorescence
immunoassay for the quantitative determination of BNP in
whole blood and plasma specimens. There is a 15 to 20 min
turn around time for the assay. When possible, BNP levels
were measured in whole blood and processed within 4 h.
When this was not possible, samples were spun down, and
the plasma was frozen until the sample was analyzed (1 to 2
days), an approach known to produce well-calibrated results
with whole blood sample methods.
Statistics. Comparisons of group means were made using t
tests for independent samples. In all cases, comparisons
were first computed using raw BNP values and then verified
with log-transformed BNP values because the BNP distri-
bution was positively skewed. Both procedures yielded
identical results.
To evaluate the association between BNP measurements
and the combined outcome, we used logistic regression. We
also performed a subgroup analysis looking at the associa-
tion between surviving discharge BNP concentration and
readmission to the hospital. In surviving patients, we also
computed a receiver-operated curve to assess whether dis-
charge BNP could be used to distinguish patients who
would later be readmitted from patients whose CHF was
successfully treated.
The number of subjects was not sufficient to permit a true
multivariate analysis of the many predictors; thus, the
analyses were conducted in a univariate manner. Each
logistic regression involved the entry of a single nominal
predictor or a continuous covariate and no other predictors.
RESULTS
Patient outcomes and BNP levels. Patients who died or
were readmitted tended to have an increase in their BNP
concentration during the course of hospitalization (1239 6
233 pg/ml); patients who had successful treatment tended to
have decreases in their BNP concentration during hospital-
ization (2216 6 69 pg/ml) (p , 0.05).
Figure 1 shows the association between BNP concentra-
tion, NYHA classification (at admission and discharge) and
patient outcome. Patients who had good outcomes tended
to be characterized by decreases in both their NYHA class
and BNP levels during hospitalization, with final BNP
levels of 690 6 103 pg/ml (Fig. 2, A1 and B1). Figure 2, A2
and B2, shows admission and last measured BNP levels and
NYHA classification in those patients who were
readmitted within 30 days of discharge. Even though the
NYHA class decreased with treatment in this group, there
were only minimal decreases in BNP levels during hospi-
talization, with a mean discharge BNP of 1,506 6
452 pg/ml. Finally, subjects who died in the hospital (Fig. 2,
A3 and B3) had rising BNP levels and little change in
symptoms.
Figure 2 shows a significant association between end
points and rising versus falling BNP levels (p , 0.001).
Abbreviations and Acronyms
BNP 5 B-type natriuretic peptide
CHF 5 congestive heart failure
LV 5 left ventricle, left ventricular
NYHA 5 New York Heart Association
SEM 5 standard error of the mean
Table 1. Patient Characteristics in 72 Patients With
Decompensated Congestive Heart Failure
Characteristic (% of patients, unless
otherwise specified)
Patient
Values
Age (mean 6 SEM) 68.0 6 1.6
Admission NYHA class (mean) 3.64 6 0.07
Ejection fraction 37% 6 2%
Etiology of heart failure
Ischemic heart failure 71.8%
Idiopathic heart failure 16.9%
Other 11.3%
Associated COPD 26.8%
Associated renal failure 25.4%
Hospital stay (days, mean) 16.1 6 2.9
Parenteral vasodilator/inotrope
(milrinone/dobutamine)
41.8%
Swan-ganz catheter placement 34.1%
End points 30.6%
Deaths 18.1%
Readmission (within 30 days) 12.5%
COPD 5 chronic obstructive pulmonary disease; NYHA 5 New York Heart
Association; SEM 5 standard error of the mean.
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Patients with falling BNP levels during treatment had only
a 16% end point rate.
Defining a potential target discharge BNP level. Table 2
shows univariate logistic regression to predict combined end
points (death or readmission) or readmission for both
discrete and continuous variables. The only historical vari-
able that significantly predicted outcomes was a previous
hospitalization of CHF (p 5 0.05). B-type natriuretic
peptide levels and admission NYHA classification were
both strong predictors of combined end points, as well as
being strong predictors of 30-day readmission subsequent
outcome. Although both admission BNP levels and the
change in BNP levels over the period of hospitalization
were significant predictors of outcome, the last measured
BNP level was the single variable that was most strongly
associated with patients experiencing one of the prespecified
end points. The mean BNP concentration was significantly
greater in patients experiencing end points (1,801 6
273 pg/ml standard error of the mean [SEM] vs. 690 6
103 pg/ml SEM) than in patients with successful treatment
of CHF (p , 0.001).
In examining the subgroup of patients surviving to
discharge, although NYHA classification was the most
significant predictor (p 5 0.0002) of readmission, discharge
BNP was also associated with readmission within 30 days
(p 5 0.02). The receiver operator curve, shown in Figure 3,
illustrates the sensitivity and specificity of BNP measure-
ments at discharge in discriminating patients who will
require readmission in 30 days from those successfully
treated for their CHF. Potential discrete cut points are
labeled. The area under the receiver operator curve was 0.72,
indicating fair to good discriminatory power. The area
under the curve (C-statistic) for all end points (death and
readmission) was 0.84.
Figure 1. B-type natriuretic peptide levels and NYHA classification before and after treatment in relation to end points or no end points (successful
treatment). Each value represents mean 6 SEM and is analyzed by analysis of variance. BNP 5 B-type natriuretic peptide; NYHA 5 New York Heart
Association.
Figure 2. The relation between end points and rising versus falling BNP
levels during treatment. Values are given as percentages and analyzed by
chi-square analysis. BNP 5 B-type natriuretic peptide (p , 0.001).
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DISCUSSION
Congestive heart failure is characterized by complicated
cardiorenal, hemodynamic and neurohormonal alterations
(16,17). Although patients who are admitted to the hospital
with decompensated heart failure often have improvement
in symptoms with the various treatment modalities avail-
able, there has been no good way to evaluate the long-term
effects of the short-term treatment. Indeed, in-hospital
mortality and readmission rates for patients with CHF are
extremely high (3,4). The conventional tests for cardiac
function take time and often do not correlate with symp-
tomatic changes in the patient’s conditions. A simple and
reliable method to assess therapeutic efficacy (“a digitalis
level”) in patients being treated for decompensated CHF is
lacking (6).
The fact that increased levels of vasoconstrictor neuro-
humoral factors such as norepinephrine, renin and
endothelin-1 have been found to be significant prognostic
predictors in CHF suggests an important role of these
vasoconstrictors in the pathogenesis of CHF (18–21).
Although they are antagonizing, these vasoconstrictors have
led to improvements in cardiac function (22,23); the use of
these markers as monitors of therapy is impractical, in large
part due to difficult assay characteristics, general instability
of markers and wide-ranging, often overlapping values
(24,25).
The vasodilator neurohumoral natriuretic peptide family
may be better candidates for neurohumoral profiling in
CHF (26). In particular, BNP has drawn recent interest in
Table 2. Univariate Predictors of End Points
History
All End Points 30 Day Readmission
Likelihood
Ratio p Value
Likelihood
ratio p Value
Age 0.51 0.37
Previous CHF admission (1 yr) 3.85 0.05 0.89
History CHF 3.06 0.08 0.2 0.4
Idiopathic 0.04 0.85 0.18 0.45
Ischemic 0.48 0.49 0.27 0.91
LV size 0.11 0.06
Ejection fraction 0.11 0.21
History of COPD 0.13 0.71 0.13 0.97
History of diabetes 0.35 0.55 2.55 0.09
History of renal disease 0.97 0.32 0.00 0.62
Hospital
Days in hospital 0.001 0.91
Admission BNP 0.003 0.03
Log admission BNP 0.001 0.01
Discharge BNP , 0.0001 0.05
Log discharge BNP , 0.0001 0.02
Delta BNP 0.020 0.7
% change BNP 0.008 0.9
Admission NYHA class 0.0004 0.354
Discharge NYHA class 0.0002
Delta NYHA class 0.204
BNP 5 B-type natriuretic peptide; CHF 5 congestive heart failure; COPD 5 chronic obstructive pulmonary disease; LV 5
left ventricle; NYHA 5 New York Heart Association.
Figure 3. Receiver operating characteristic curves for patients with decom-
pensated congestive heart failure compares the sensitivity and specificity of
BNP measurements to 30-day readmission rates. Discrete cut-points are
labeled. The AUC (C-statistic) was 0.72 for readmission. Sensitivity,
specificity, positive and negative predictive values and accuracy are recorded
for each cut-point of the receiver operating characteristic curve. AUC 5
area under the curve; BNP 5 B-type natriuretic peptide.
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its ability to match the decompensated state of circulatory
congestion (13,14,27–31).
B-type natriuretic peptide is a 32-aa polypeptide contain-
ing a 17-aa ring structure common to all natriuretic peptides
(32,33). The source of plasma BNP is cardiac ventricles,
which suggests that it may be a more sensitive and specific
indicator of ventricular disorders than other natriuretic
peptides (6,7,34). Tsutamoto et al. (34) found that plasma
BNP was more useful than ANP or norepinephrine for
assessing the mortality in patients with chronic CHF and
that plasma levels of BNP provided prognostic information
independent of other variables previously associated with a
poor prognosis.
Although extensive guidelines have been published on the
outpatient management of patients with CHF or asymp-
tomatic LV dysfunction (35), few guidelines address appro-
priate management during the period of inpatient hospital-
ization (the phase of care that contributes highly to
morbidity and cost). This is the first study that specifically
examines outcomes of patients admitted for decompensated
CHF using BNP levels drawn throughout hospitalization.
Our data suggest that rapid testing of BNP may someday be
used to tailor treatment of patients admitted with decom-
pensated heart failure.
Patients whose discharge BNP level fell below
1,220 pg/ml with treatment in the hospital had a reasonable
likelihood of leaving the hospital in good condition and not
being readmitted within the following 30 days. A final BNP
level #430 pg/ml had a strong negative predictive value for
readmission. This level is similar to that seen in a group of
200 patients with LV dysfunction on echocardiography with
no previous diagnosis of CHF (36). This level also correlates
to NYHA classification of approximately class II to III ([37]
and personal observation).
Why is plasma BNP a useful predictor of decompensated
CHF outcome? B-type natriuretic peptide is a truly ven-
tricular hormone. There is a direct relationship between
ventricular wall stress and secretion of BNP (28). B-type
natriuretic peptide responds to changes in LV filling pres-
sure (28,29). The nucleic acid sequence of the BNP gene
contains the destabilizing sequence “tatttat,” which suggests
that turnover of BNP messenger RNA is high and that
BNP is synthesized in bursts (38–40). Cheung et al. (41)
has suggested that BNP level reflects long-term intravascu-
lar volume status rather than momentary volume. Our data
agree more with Tsutamoto and others (34,42), whose data
suggest that BNP is the emergency hormone that responds
immediately to ventricular overload.
Study limitations. This was an observational study con-
ducted using a prospective retrospective design in a conve-
nience sample of male patients. As such, the data must be
interpreted with caution. Because of the small sample size,
multivariate analysis was not performed. Regression studies
present the fit of parameters to observed data rather than the
predictive performance.
Point-of-care testing and tailored treatment for decom-
pensated heart failure—is there a future? The correlation
between the drop in BNP level and the patient’s improve-
ment in symptoms (and subsequent outcome) suggests that
BNP guided treatment might make “tailored therapy” more
effective and, in some cases, might reduce the need for
invasive hemodynamic monitoring in selected patients. Al-
though there has not been sufficient testing of the value of
plasma protein measurements for tailoring therapy of CHF
once the patient has been discharged (43), several research
groups have recently reported data suggesting that BNP
measurements may be useful in the adjustment of medica-
tions in heart failure (43–46).
In conclusion, the data presented in previously published
papers, when combined with the results of this study,
suggest that point-of-care testing of BNP may be an
effective way to improve the in-hospital management of
patients admitted with decompensated CHF. Future studies
should examine the feasibility and outcomes of BNP-
directed therapy of CHF using point-of-care measure-
ments.
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